

Special Issue

Pharmacokinetics and Pharmacodynamics of Antibacterial and Antivirulence Drugs, 2nd Edition

Message from the Guest Editor

Recognizing that antibiotic resistance remains a global challenge, this Special Issue continues to explore the critical relationship between drug concentrations and therapeutic outcomes. We welcome submissions on topics including, but not limited to, the following:

- Pharmacokinetic (PK) and pharmacodynamic (PD) studies of novel antibacterial or antivirulence compounds.
- In vitro characterizations to understand PK/PD relationships of new or established antibacterial or antivirulence agents.
- In silico PK or PK/PD modeling approaches aimed at translating early-stage compounds into clinical applications.
- Animal PK or PK/PD studies of established antibacterial compounds with implications for current treatment regimens.
- PK studies of established antibacterial compounds in special patient populations.
- PK or PK/PD modeling approaches to study and enhance therapeutic effects in special patient populations.

If you have any concerns regarding publication fees or require financial support, please contact the Editorial Office (Ms. Lyric Ren, lyric.ren@mdpi.com) for further assistance.

Guest Editor

Prof. Dr. Takahisa Yano
Department of Pharmacy, Shimane University Hospital, 89-1 Enya,
Izumo 693-8501, Japan

Deadline for manuscript submissions

28 February 2027



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.2
Indexed in PubMed



mdpi.com/si/232159

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.2
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)